Cargando…

Clinical Outcome of Remnant Thyroid Ablation with Low Dose Radioiodine in Korean Patients with Low to Intermediate-risk Thyroid Cancer

Radioiodine activity required for remnant thyroid ablation is of great concern, to avoid unnecessary exposure to radiation and minimize adverse effects. We investigated clinical outcomes of remnant thyroid ablation with a low radioiodine activity in Korean patients with low to intermediate-risk thyr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ha, Seunggyun, Oh, So Won, Kim, Yu Kyeong, Koo, Do Hoon, Jung, Young Ho, Yi, Ka Hee, Chung, June-Key
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Academy of Medical Sciences 2015
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4479940/ https://www.ncbi.nlm.nih.gov/pubmed/26130949 http://dx.doi.org/10.3346/jkms.2015.30.7.876

Ejemplares similares

Low versus high radioiodine activity for ablation of the thyroid remnant after thyroidectomy in Han Chinese with low-risk differentiated thyroid cancer
por: Lv, Rong-Bin, et al.
Publicado: (2017)

The role of Hashimoto thyroiditis in predicting radioiodine ablation efficacy and prognosis of low to intermediate risk differentiated thyroid cancer
por: Albano, Domenico, et al.
Publicado: (2021)

The Effectiveness of Recombinant Human Thyroid-Stimulating Hormone versus Thyroid Hormone Withdrawal Prior to Radioiodine Remnant Ablation in Thyroid Cancer: A Meta-Analysis of Randomized Controlled Trials
por: Pak, Kyoungjune, et al.
Publicado: (2014)

Efficacy of Low-Dose Radioiodine Ablation in Low- and Intermediate-Risk Differentiated Thyroid Cancer: A Retrospective Comparative Analysis
por: Gómez-Pérez, Ana María, et al.
Publicado: (2020)

Radioiodine remnant ablation in low-risk differentiated thyroid cancer patients who had R0 dissection is an over treatment
por: Bal, Chandrasekhar, et al.
Publicado: (2015)

Radioiodine Thyroid Remnant Ablation after Recombinant Human Thyrotropin or Thyroid Hormone Withdrawal in Patients with High-Risk Differentiated Thyroid Cancer
por: Pitoia, Fabián, et al.
Publicado: (2012)

Scintigraphic evaluation of salivary gland function in thyroid cancer patients after radioiodine remnant ablation
por: Krčálová, Eva, et al.
Publicado: (2020)

Assessment of Different Radioiodine Doses for Post-ablation Therapy of Thyroid Remnants: A Systematic Review
por: Ansari, Mojtaba, et al.
Publicado: (2022)

Radioiodine remnant ablation in stage I adult papillary thyroid carcinoma: does it improve postoperative outcome?
por: Hay, Ian D, et al.
Publicado: (2022)

Diagnosis and Treatment of Acute Pleural Effusion following Radioiodine Remnant Ablation Post Lobectomy for Thyroid Cancer
por: Qiu, Xian, et al.
Publicado: (2022)

Assessment of three different radioiodine doses for ablation therapy of thyroid remnants: Efficiency, complications and patient comfort
por: Soyluoglu, Selin, et al.
Publicado: (2023)

SAT525 Long-Term Outcomes in Stage I Thyroid Cancer Without Radioiodine Remnant Ablation
por: Mubeen, Faiza, et al.
Publicado: (2023)

Clinical Outcomes after Early and Delayed Radioiodine Remnant Ablation in Patients with Low-Risk Papillary Thyroid Carcinoma: Propensity Score Matching Analysis
por: Ahn, Jonghwa, et al.
Publicado: (2020)

Regional Variation across Canadian Centers in Radioiodine Administration for Thyroid Remnant Ablation in Well-Differentiated Thyroid Cancer Diagnosed in 2000–2010
por: Rachinsky, I., et al.
Publicado: (2016)

Radioiodine Remnant Ablation: A Critical Review
por: Bal, Chandra Sekhar, et al.
Publicado: (2015)

Ablation therapy using a low dose of radioiodine may be sufficient in low- to intermediate-risk patients with follicular variant papillary thyroid carcinoma
por: Li, Fuxin, et al.
Publicado: (2020)

Comparing High and Low-Dose Radio-Iodine Therapy in Thyroid Remnant Ablation Among Intermediate and Low-Risk Papillary Thyroid Carcinoma Patients—Single Centre Experience
por: Yasmin, Tahira, et al.
Publicado: (2021)

Strong Neck Accumulation of (131)I Is a Predictor of Incomplete Low-Dose Radioiodine Remnant Ablation Using Recombinant Human Thyroid-Stimulating Hormone
por: Enomoto, Keisuke, et al.
Publicado: (2015)

Radioiodine Therapy in Differentiated Thyroid Cancer: The First Targeted Therapy in Oncology
por: Chung, June-Key, et al.
Publicado: (2014)

A Phase II Multi-Center, Non-Randomized, Parallel Group, Non-Inferiority Study to Compare the Efficacy of No Radioactive Iodine Remnant Ablation to Remnant Ablation Treatment in Low- to Intermediate-Risk of Papillary Thyroid Cancer: The MOREthyroid Trial Protocol
por: Lee, Eun Kyung, et al.
Publicado: (2020)

Radioiodine (131I) treatment decision-making for low- and intermediate-risk differentiated thyroid cancer
por: Gao, Haiyan, et al.
Publicado: (2023)

Economic Evaluation of Recombinant Human Thyroid Stimulating Hormone Stimulation vs. Thyroid Hormone Withdrawal Prior to Radioiodine Ablation for Thyroid Cancer: The Korean Perspective
por: Sohn, Seo Young, et al.
Publicado: (2015)

Radioiodine remnant ablation of differentiated thyroid cancer does not further increase oxidative damage to membrane lipids - early effect
por: Makarewicz, Jacek, et al.
Publicado: (2010)

A pre-ablative thyroid-stimulating hormone with 30–70 mIU/L achieves better response to initial radioiodine remnant ablation in differentiated thyroid carcinoma patients
por: Xiao, Juan, et al.
Publicado: (2021)

Radioiodine Thyroid Ablation in Graves’ Hyperthyroidism: Merits and Pitfalls
por: Nwatsock, J. F., et al.
Publicado: (2012)

Radioiodine thyroid remnant ablation in patients with differentiated thyroid carcinoma (DTC): prospective comparison of long-term outcomes of treatment with 30, 60 and 100 mCi
por: Kukulska, Aleksandra, et al.
Publicado: (2010)

Thyroid remnant ablation with radioiodine activity of 30, 60, and 100 mCi in patients with differentiated thyroid cancer – a prospective comparison of long-term outcomes
por: Kukulska, Aleksandra, et al.
Publicado: (2020)

The Optimal Activity of Radioactive Iodine for Remnant Ablation in Low/Intermediate Risk Differentiated Thyroid Carcinoma: A Continuous Controversy and Meta-Analysis
por: Mirghani, Hyder, et al.
Publicado: (2021)

Longer-term recurrence rate after low versus high dose radioiodine ablation for differentiated thyroid Cancer in low and intermediate risk patients: a meta-analysis
por: Vardarli, I., et al.
Publicado: (2020)

Low vs. High Radioiodine Activity to Ablate the Thyroid after Thyroidectomy for Cancer: A Randomized Study
por: Mäenpää, Hanna O., et al.
Publicado: (2008)

Myopathy following postoperative ablative radioiodine for follicular carcinoma of the thyroid
por: Price, Hermione C, et al.
Publicado: (2009)

Adjuvant Radioiodine for Intermediate-Risk Papillary Thyroid Cancer—To Treat or Not to Treat
por: van Velsen, Evert F S, et al.
Publicado: (2023)

Adjuvant treatment with thyrotropin alpha for remnant ablation in thyroid cancer
por: Biondi, Bernadette, et al.
Publicado: (2009)

Radioiodine for thyroid cancer: sometimes, less is best
por: Padovani, Rosalia do Prado
Publicado: (2016)

Comparison of radioiodine ablation rates between low versus high dose, and according to the surgeon's expertise in the low-risk group of differentiated thyroid cancer
por: Norouzi, Ghazal, et al.
Publicado: (2020)

2017 Thyroid Radiofrequency Ablation Guideline: Korean Society of Thyroid Radiology
por: Kim, Ji-hoon, et al.
Publicado: (2018)

Thyroid Lobectomy for Low to Intermediate Risk Differentiated Thyroid Cancer
por: Hartl, Dana M., et al.
Publicado: (2020)

Heath-related quality of life in thyroid cancer patients following radioiodine ablation
por: Taïeb, David, et al.
Publicado: (2011)

Ethanol Ablation of the Thyroid Nodules: 2018 Consensus Statement by the Korean Society of Thyroid Radiology
por: Hahn, Soo Yeon, et al.
Publicado: (2019)

Acute Myeloid Leukemia after Low-Dose Radioiodine Therapy for Papillary Thyroid Carcinoma
por: Alsaud, Arwa, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_5baop8kh72rl6ue018tvf5j04r